

New Listing Portfolio Introduction–

SynCore Biotechnology Co., Ltd

SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutical company focusing on creating values of new drug by R&D and integration of technology resources. SynCore was established in 2008 and co-founded by Sinphar Group and National Health Research Institute (also known as NHRI). SynCore inherited Sinphar Group’s experiences which have been accumulated for more than 30 years in R&D, manufacturing, and international marketing. Such experiences enable SynCore to build up the comprehensive pipeline portfolio for new drug development to fulfill domestic and international market needs and to consolidate the future development.

SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs with great marketing potential. By professional and expeditious project management, SynCore accumulates intangible assets to promote its marketing values. SynCore keeps looking for international partners actively and guarantees stable and long-term profits through strategic alliance to enrich sustainable operating energy.

Hotung Group has invested in SynCore since March 2013. SynCore has been approved by Taiwan GreTai Securities Market (“GTSM”) and plans to debut on GTSM on the 28th of October 2014.

BY ORDER OF THE BOARD

Shu-Hui Lo

Company Secretary

October 28, 2014